397 related articles for article (PubMed ID: 16353138)
21. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
22. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
23. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
24. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
25. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
26. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
27. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.
de Vries IJ; Bernsen MR; Lesterhuis WJ; Scharenborg NM; Strijk SP; Gerritsen MJ; Ruiter DJ; Figdor CG; Punt CJ; Adema GJ
J Clin Oncol; 2005 Aug; 23(24):5779-87. PubMed ID: 16110035
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
30. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
[TBL] [Abstract][Full Text] [Related]
31. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
32. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
33. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.
Liénard D; Rimoldi D; Marchand M; Dietrich PY; van Baren N; Geldhof C; Batard P; Guillaume P; Ayyoub M; Pittet MJ; Zippelius A; Fleischhauer K; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2004 May; 4():4. PubMed ID: 15149168
[TBL] [Abstract][Full Text] [Related]
34. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
[TBL] [Abstract][Full Text] [Related]
35. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
36. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
[TBL] [Abstract][Full Text] [Related]
38. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J
Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640
[TBL] [Abstract][Full Text] [Related]
39. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
40. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.
Mahnke K; Schönfeld K; Fondel S; Ring S; Karakhanova S; Wiedemeyer K; Bedke T; Johnson TS; Storn V; Schallenberg S; Enk AH
Int J Cancer; 2007 Jun; 120(12):2723-33. PubMed ID: 17315189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
